CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00388-07v1
15/1/76    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Go, Y. Y.
Right arrow Articles by Balasuriya, U. B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Go, Y. Y.
Right arrow Articles by Balasuriya, U. B. R.
Clinical and Vaccine Immunology, January 2008, p. 76-87, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00388-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Development of a Fluorescent-Microsphere Immunoassay for Detection of Antibodies Specific to Equine Arteritis Virus and Comparison with the Virus Neutralization Test{triangledown}

Yun Young Go,1 Susan J. Wong,2 Adam J. Branscum,3 Valerie L. Demarest,2 Kathleen M. Shuck,1 Mary L. Vickers,4 Jianqiang Zhang,1 William H. McCollum,1 Peter J. Timoney,1 and Udeni B. R. Balasuriya1*

Maxwell H. Gluck Equine Research Center, Department of Veterinary Science,1 College of Public Health,3 Livestock Disease Diagnostic Center, University of Kentucky, Lexington, Kentucky 40546,4 Wadsworth Center, New York State Department of Health, Albany, New York 122012

Received 26 September 2007/ Returned for modification 23 October 2007/ Accepted 5 November 2007

The development and validation of a microsphere immunoassay (MIA) to detect equine antibodies to the major structural proteins of equine arteritis virus (EAV) are described. The assay development process was based on the cloning and expression of genes for full-length individual major structural proteins (GP5 amino acids 1 to 255 [GP51-255], M1-162, and N1-110), as well as partial sequences of these structural proteins (GP51-116, GP575-112, GP555-98, M88-162, and N1-69) that constituted putative antigenic regions. Purified recombinant viral proteins expressed in Escherichia coli were covalently bound to fluorescent polystyrene microspheres and analyzed with the Luminex xMap 100 instrument. Of the eight recombinant proteins, the highest concordance with the virus neutralization test (VNT) results was obtained with the partial GP555-98 protein. The MIA was validated by testing a total of 2,500 equine serum samples previously characterized by the VNT. With the use of an optimal median fluorescence intensity cutoff value of 992, the sensitivity and specificity of the assay were 92.6% and 92.9%, respectively. The GP555-98 MIA and VNT outcomes correlated significantly (r = 0.84; P < 0.0001). Although the GP555-98 MIA is less sensitive than the standard VNT, it has the potential to provide a rapid, convenient, and more economical test for screening equine sera for the presence of antibodies to EAV, with the VNT then being used as a confirmatory assay.


* Corresponding author. Mailing address: 108 Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY 40546. Phone: (859) 257-4757, ext. 81124. Fax: (859) 257-8542. E-mail: ubalasuriya{at}uky.edu

{triangledown} Published ahead of print on 21 November 2007.


Clinical and Vaccine Immunology, January 2008, p. 76-87, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00388-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.